Table 4 |
||
|
Adverse events after intervention. |
||
|
Characteristics |
Vitamin C Group (n = 70) |
Placebo Group (n = 71) |
|
|
||
|
Withdrawal from trial for adverse events, n (%) |
0 (0) |
0 (0) |
|
|
||
|
Patients with ≥ 1 adverse events 2 hours after trial, n (%) |
16 (22.9) |
11 (15.4) |
|
|
||
|
Patients with ≥ 1 adverse events 1 day after trial, n (%) |
4 (5.7) |
4 (5.6) |
|
|
||
|
Total adverse events, n |
24 |
17 |
|
|
||
|
Patients who experienced specific adverse events 2 hours after intervention, n (%) |
||
|
itching sense/pain at injection site |
9 (12.9) |
8 (11.3) |
|
dry mouth |
7 (10) |
2 (2.8) |
|
others* |
4 (5.7) |
3 (4.2) |
|
|
||
|
Patients who experienced specific adverse events 1 day after intervention, n (%) |
||
|
itching sense/pain at injection site |
1 (1.4) |
3 (4.2) |
|
dry mouth |
1 (1.4) |
0 (0) |
|
diarrhea |
1 (1.4) |
0 (0) |
|
common cold symptoms |
1 (1.4) |
1 (1.4) |
|
|
||
|
*Other adverse events included chest discomfort, palpitations, sweating, and abdominal discomfort in the vitamin C group and dizziness, fatigue, and myalgias in the placebo group. These adverse events occurred in one case each. |
||
|
Suh et al. Nutrition Journal 2012 11:7 doi:10.1186/1475-2891-11-7 |
||
